TEST DETAILS

Test Code and Name:
TH68 Novel Coronavirus COVID-19 Nasopharynx
TH69 Novel Coronavirus COVID-19 Oropharynx
TH71 Novel Coronavirus COVID-19 Pooled NP/OP

Primary Container: Dacron-tipped plastic swab with universal transport media (Speedy# 510)
MAY INCLUDE ONE OF THE FOLLOWING:
• M6MicroTipFlockSwab
• M4MicroTipFlockSwab
• M6UniversalFlockSwab
• StarSwab

Alternate Container: Swab Viral Culturette (Speedy# 509)

Turn Around Time*: 3 Days

Transportation Temperature: Refrigerate

Stability: 3 days (Refrigerated at 2–8° C)

Methodology: Real Time RT-PCR

Reference Range: Not Detected

Result Comments:
• Presumptive Positive 2019-nCoV: Critical
• Inconclusive: Recommend Repeat Testing As Clinically Indicated
• Invalid: Recommend Repeat Testing As Clinically Indicated
• Not Detected: Consider Re-Collection As Clinically Indicated

NOTE: All results, positive, negative and inconclusive, will be reported to the respective state health departments through ELR (Electronic Laboratory Reporting).

Specimen Collection: Patients under investigation of COVID-19 and seeking evaluation of the disease will not be collected at Ammon Labs Patient Service Centers. Specimen should be collected at physician offices, hospitals or other clinic settings. Use standard technique for Nasopharyngeal or Oropharyngeal collection, and immediately place in 2–3 mL of viral transport media. Refrigerate specimen at 2–8° C. Label patient information. Place in specimen bag and label with “COVID-19” and submit to laboratory. NOT TO BE USED FOR BACTERIAL TRANSPORT.

AOEs: Source:
☐ Oropharyngeal  ☐ Nasopharyngeal

Price:
List Price: $150
Self-Pay Price: $110

Clinical Utility: For the detection of the novel COVID-19, Coronavirus

*TAT is based upon receipt of the specimen at the laboratory.

SOURCES


For more information please call 877-969-0004
or email info@ammonlabs.com

35 E. Blanke Street
Linden, NJ 07036

COVID-19
Testing information for healthcare providers

This COVID-19 assay provides you with accurate and timely test results to provide proper care and reduce subsequent spread of infection.
NOVEL CORONAVIRUS DISEASE: COVID-19

The novel coronavirus disease (COVID-19) is a new virus of global health significance caused by infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). On March 11, 2020, the World Health Organization (WHO) declared COVID-19 a global pandemic.

TRANSMISSION AND SYMPTOMS
According to the U.S. Centers for Disease Control and Prevention (CDC), COVID-19 is thought to spread from person to person in close contact through respiratory droplets. It is also possible that a person can catch COVID-19 by touching a surface or object that has the virus on it. The CDC reports that the following symptoms may appear 2–14 days after exposure:
• Fever • Cough • Shortness of breath

DIAGNOSTIC TESTING FOR COVID-19
Ammon Labs offers a real-time reverse-transcription polymerase chain reaction (real-time RT-PCR) assay, giving healthcare providers accurate and timely test results to ensure greater access to testing, promote earlier diagnosis and help limit the subsequent spread of infection. The test detects the presence of SARS-CoV-2 and is for use with patients who meet current guidance for evaluation of infection with COVID-19.

The test has been made available pursuant to the US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for diagnostic testing in CLIA Certified high-complexity laboratories. The test has been validated.

Please refer to the ICD-10 Coding Guidelines for more information on coding encounters related to the 2019 novel coronavirus (COVID-19).

GUIDANCE FOR TESTING
The CDC has released criteria for healthcare providers for the evaluation of patients under investigation (PUI) of COVID-19. As of March 4, 2020 recommendations include testing for a wider group of symptomatic patients. Providers should use their judgment to determine if a patient has signs and symptoms compatible with COVID-19 and whether the patient should be tested. Decisions on which patients receive testing should be based on the local epidemiology of COVID-19, as well as the clinical course of illness. Please refer to the most current CDC guidelines for further information.


Healthcare providers should notify their local or state health department immediately in the event of a patient under investigation for COVID-19.

COLLECTION INSTRUCTIONS
Patients under investigation of COVID-19 and seeking evaluation of the disease will not be collected at Ammon Labs’ Patient Service Centers. Specimen should be collected at physician offices, hospitals or other clinic settings using Nasopharyngeal or Oropharyngeal collection, and immediately placed in 2–3 mL of viral transport media. Please place in specimen bag and label with “COVID-19” for submission to Ammon Labs. Refrigerate specimen at 2–8° C.

STANDARD PROCEDURES FOR NASOPHARYNGEAL COLLECTION

1. Tilt patient’s head so nasal passages are parallel to the palate.
2. Insert a swab into nostril. Leave the swab in place for several seconds to absorb secretions.
3. Slowly remove swab while rotating it.

STANDARD PROCEDURES FOR OROPHARYNGEAL COLLECTION

1. Swab the posterior pharynx, avoid touching the tongue, teeth, and gums.
2. Remove swab.